302 related articles for article (PubMed ID: 18842137)
1. Quantifying information transfer by protein domains: analysis of the Fyn SH2 domain structure.
Lenaerts T; Ferkinghoff-Borg J; Stricher F; Serrano L; Schymkowitz JW; Rousseau F
BMC Struct Biol; 2008 Oct; 8():43. PubMed ID: 18842137
[TBL] [Abstract][Full Text] [Related]
2. Heteronuclear NMR studies of the combined Src homology domains 2 and 3 of pp60 c-Src: effects of phosphopeptide binding.
Tessari M; Gentile LN; Taylor SJ; Shalloway DI; Nicholson LK; Vuister GW
Biochemistry; 1997 Nov; 36(47):14561-71. PubMed ID: 9398174
[TBL] [Abstract][Full Text] [Related]
3. Interactions between the Fyn SH3-domain and adaptor protein Cbp/PAG derived ligands, effects on kinase activity and affinity.
Solheim SA; Petsalaki E; Stokka AJ; Russell RB; Taskén K; Berge T
FEBS J; 2008 Oct; 275(19):4863-74. PubMed ID: 18721137
[TBL] [Abstract][Full Text] [Related]
4. Binding of the proline-rich segment of myelin basic protein to SH3 domains: spectroscopic, microarray, and modeling studies of ligand conformation and effects of posttranslational modifications.
Polverini E; Rangaraj G; Libich DS; Boggs JM; Harauz G
Biochemistry; 2008 Jan; 47(1):267-82. PubMed ID: 18067320
[TBL] [Abstract][Full Text] [Related]
5. The SH2 domain from the tyrosine kinase Fyn in complex with a phosphotyrosyl peptide reveals insights into domain stability and binding specificity.
Mulhern TD; Shaw GL; Morton CJ; Day AJ; Campbell ID
Structure; 1997 Oct; 5(10):1313-23. PubMed ID: 9351806
[TBL] [Abstract][Full Text] [Related]
6. Prediction of solvation sites at the interface of Src SH2 domain complexes using molecular dynamics simulations.
Geroult S; Hooda M; Virdee S; Waksman G
Chem Biol Drug Des; 2007 Aug; 70(2):87-99. PubMed ID: 17683370
[TBL] [Abstract][Full Text] [Related]
7. Dynamically Coupled Residues within the SH2 Domain of FYN Are Key to Unlocking Its Activity.
Huculeci R; Cilia E; Lyczek A; Buts L; Houben K; Seeliger MA; van Nuland N; Lenaerts T
Structure; 2016 Nov; 24(11):1947-1959. PubMed ID: 27692963
[TBL] [Abstract][Full Text] [Related]
8. Alternative mode of binding to phosphotyrosyl peptides by Src homology-2 domains.
Qin C; Wavreille AS; Pei D
Biochemistry; 2005 Sep; 44(36):12196-202. PubMed ID: 16142918
[TBL] [Abstract][Full Text] [Related]
9. Structure of human Fyn kinase domain complexed with staurosporine.
Kinoshita T; Matsubara M; Ishiguro H; Okita K; Tada T
Biochem Biophys Res Commun; 2006 Aug; 346(3):840-4. PubMed ID: 16782058
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors to the Src SH2 domain: a lesson in structure--thermodynamic correlation in drug design.
Henriques DA; Ladbury JE
Arch Biochem Biophys; 2001 Jun; 390(2):158-68. PubMed ID: 11396918
[TBL] [Abstract][Full Text] [Related]
11. A quantum mechanical study on phosphotyrosyl peptide binding to the SH2 domain of p56lck tyrosine kinase with insights into the biochemistry of intracellular signal transduction events.
Pichierri F
Biophys Chem; 2004 May; 109(2):295-304. PubMed ID: 15110947
[TBL] [Abstract][Full Text] [Related]
12. Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase.
Nagar B; Hantschel O; Seeliger M; Davies JM; Weis WI; Superti-Furga G; Kuriyan J
Mol Cell; 2006 Mar; 21(6):787-98. PubMed ID: 16543148
[TBL] [Abstract][Full Text] [Related]
13. Identification of a collapsed intermediate with non-native long-range interactions on the folding pathway of a pair of Fyn SH3 domain mutants by NMR relaxation dispersion spectroscopy.
Neudecker P; Zarrine-Afsar A; Choy WY; Muhandiram DR; Davidson AR; Kay LE
J Mol Biol; 2006 Nov; 363(5):958-76. PubMed ID: 16989862
[TBL] [Abstract][Full Text] [Related]
14. Superbinder SH2 domains act as antagonists of cell signaling.
Kaneko T; Huang H; Cao X; Li X; Li C; Voss C; Sidhu SS; Li SS
Sci Signal; 2012 Sep; 5(243):ra68. PubMed ID: 23012655
[TBL] [Abstract][Full Text] [Related]
15. Design and biological evaluation of linear and cyclic phosphopeptide ligands of the N-terminal SH2 domain of protein tyrosine phosphatase SHP-1.
Imhof D; Wieligmann K; Hampel K; Nothmann D; Zoda MS; Schmidt-Arras D; Zacharias M; Böhmer FD; Reissmann S
J Med Chem; 2005 Mar; 48(5):1528-39. PubMed ID: 15743195
[TBL] [Abstract][Full Text] [Related]
16. SH2 domains: role, structure and implications for molecular medicine.
Waksman G; Kumaran S; Lubman O
Expert Rev Mol Med; 2004 Jan; 6(3):1-18. PubMed ID: 14987415
[TBL] [Abstract][Full Text] [Related]
17. The role of water in computational and experimental derivation of binding thermodynamics in SH2 domains.
Geroult S; Virdee S; Waksman G
Chem Biol Drug Des; 2006 Jan; 67(1):38-45. PubMed ID: 16492147
[TBL] [Abstract][Full Text] [Related]
18. Characterization of domain-peptide interaction interface: a case study on the amphiphysin-1 SH3 domain.
Hou T; Zhang W; Case DA; Wang W
J Mol Biol; 2008 Feb; 376(4):1201-14. PubMed ID: 18206907
[TBL] [Abstract][Full Text] [Related]
19. Homology modeling of human Fyn kinase structure: discovery of rosmarinic acid as a new Fyn kinase inhibitor and in silico study of its possible binding modes.
Jelić D; Mildner B; Kostrun S; Nujić K; Verbanac D; Culić O; Antolović R; Brandt W
J Med Chem; 2007 Mar; 50(6):1090-100. PubMed ID: 17315853
[TBL] [Abstract][Full Text] [Related]
20. Determination of Leu side-chain conformations in excited protein states by NMR relaxation dispersion.
Hansen DF; Neudecker P; Vallurupalli P; Mulder FA; Kay LE
J Am Chem Soc; 2010 Jan; 132(1):42-3. PubMed ID: 20000605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
